Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Speculation is mounting around a potential acquisition involving Incyte Corporation ($INCY), with rumors suggesting Novartis ($NVS) as a possible buyer. Reports in Swiss financial newspaper 'Finanz und Wirtschaft' and other sources have fueled discussions, particularly following the retention of the Hogna Howell M&A team by Incyte on September 9. Additionally, Novartis CEO previously mentioned interest in acquisitions exceeding $10 billion in a November 3 interview but later downplayed this on November 21. Journalist Mark Kleinman has also reported Merck as an interested party. The mention of a power of attorney adds another layer to the speculation. Market observers are closely monitoring developments as Incyte has yet to respond to investor inquiries regarding these speculations.
$INCY to sum up my thesis 1. Power of attorney is a real fact 2. NVS CEO mentioned 10b+ acquisitions on Nov 3 Interview 3. NVS CEO on nov 21 talked that statement down 4. @MarkKleinmanSky said @merck was an interested party! @MarkKleinmanSky has one of the best track records,…
$INCY ... did the company just stop replying to investors Enquires today? ⚠️maybe they will rash the same way Novartis (of the other buyer I think) did ... when Morphosys was bought ⁉️ ‼️READ BACKGROUND OF THE MERGER BELOW‼️ FYI, I know @unemon1 research has made it to the… https://t.co/Ot7emAKkt9
$INCY ... sound like ... the story it was on the front page of "Finanz Und Wirtschaft" printed Edition! and it's gaining traction! I guess it will be hard for Incyte not to comment now! Hilarious no shout out to @unemon1 .. when it seems like 70% of the content in the article…
